Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corp (DXR) delivers critical advancements in blood volume measurement through its FDA-cleared BVA-100 technology. This page provides investors and healthcare professionals with centralized access to official news, financial updates, and clinical developments related to DXR’s diagnostic innovations.
Track press releases covering product milestones, peer-reviewed research validations, and strategic partnerships. Stay informed about quarterly earnings, regulatory filings, and advancements in fluid management diagnostics. All content is sourced directly from verified company communications to ensure accuracy.
Key updates include BVA-100 adoption metrics, clinical trial outcomes, and operational expansions. Bookmark this page for real-time insights into DXR’s role in transforming patient diagnostics through precise blood volume analysis. Regularly updated to serve as your primary resource for unbiased, factual Daxor Corp developments.
Daxor Corporation (DXR) announced significant findings from a Duke University Medical Center study published in the American Heart Journal regarding Blood Volume Analysis (BVA) in heart failure patients. The research demonstrates BVA's effectiveness in differentiating between true and dilutional anemia in heart failure patients.
Key findings revealed that among heart failure patients diagnosed with anemia, 60% had true anemia while 40% had dilutional pseudo-anemia. Patients with dilutional pseudo-anemia showed higher tendencies toward heart failure hospitalization. The study also found that heart failure patients with red blood cell mass deficit or true anemia demonstrated poorer exercise capacity.
The research validates BVA's importance in heart failure management, as standard blood panels are not sufficiently sensitive or specific for this purpose.
Daxor Corporation (DXR) has expanded its blood volume measurement technology to two new U.S. healthcare systems. The expansion includes: 1) Implementation of the ezBVA Lab service at a premier regional referral center in East Tennessee, providing comprehensive diagnostic results within 24 hours for outpatient cardiology services, and 2) Installation of an on-site BVA analyzer system at a leading healthcare facility in the Pacific Northwest for both inpatient and outpatient diagnostic needs.
The company's dual implementation model offers flexibility through both laboratory services and on-site systems. Daxor's proprietary technology provides gold-standard blood volume measurements that have been proven to reduce mortality, hospital readmissions, and length of stay in heart failure and critical care patients.
Daxor Corporation (DXR) has expanded its presence in Florida by launching a new Blood Volume Analysis (BVA) program at a major healthcare center in Tampa Bay. The facility will utilize Daxor's Tennessee-based CLIA-certified ezBVA Lab service, which provides blood volume analysis results within 24 hours of sample receipt.
The service offers 98% accurate measurements for fluid management in various conditions including cardiac, renal, and critical care. The ezBVA Lab service eliminates the need for capital investment while maintaining full reimbursement through CPT codes under both public and private insurance plans.
Daxor Corporation (DXR) has expanded its blood volume analysis (BVA) capabilities by adding three new medical centers to its network. The expansion is driven by the company's ezBVA Lab service, a CLIA-certified facility that provides precise blood volume analysis results within 24 hours. The new adoptions include a leading regional referral center in Philadelphia's northern suburbs, a premier northern Kentucky hospital, and an Arkansas community hospital.
The ezBVA Lab service operates on a zero-capital investment model with full reimbursement coverage, making it an attractive solution for healthcare providers. All three facilities will implement the service primarily for outpatient heart failure management, with potential for inpatient expansion.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, announces its participation in the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting from April 27-30, 2025, in Boston, MA. The event, which attracts approximately 3,500 international specialists in advanced heart and lung disease treatment, will be held at the John B. Hynes Veterans Memorial Convention Center.
The company will showcase its blood volume analysis technology at Booth 305. According to CEO Michael Feldschuh, their diagnostic solution provides 98% accurate data for personalized treatment in both inpatient and outpatient settings, aimed at improving outcomes while reducing care duration and costs.
Daxor (DXR) announces its participation in the MedAxiom CV Transforum Spring'25 Conference in Orlando, FL from April 24-26, 2025. The event will feature a presentation by WellStar Health System's Dr. Brian Howard, highlighting their successful implementation of blood volume analysis (BVA) technology in reducing acute kidney injury rates following left ventricular assist device implantation.
The company's BVA-guided care has demonstrated significant improvements in patient outcomes according to peer-reviewed studies, including:
- 82% reduction in 30-day mortality
- 86% reduction in 1-year mortality
- 56% reduction in 30-day readmissions
- 55% reduction in length of stay when performed on admission
Daxor's BVA technology provides 98% accurate data for optimizing treatment plans and individualizing patient care, leading to improved outcomes and reduced care costs.
Daxor (DXR) announced significant research findings at the American College of Cardiology's 74th Annual Scientific Session, demonstrating improved survival rates in heart failure patients using their blood volume analysis (BVA) technology. The study, conducted by Minneapolis Heart Institute Foundation and Allina Health, analyzed 1,237 heart failure patients, with 202 receiving BVA testing near discharge.
Key findings revealed that patients confirmed as 'euvolemic' (normal blood volume) through BVA showed 2.61 times better survival rates compared to hypervolemic (congested) patients. The study demonstrated a strong statistical significance (p=0.002), and the correlation between blood volume status and survival persisted even after adjusting for comorbidities.
Daxor (Nasdaq: DXR) has submitted its next-generation blood volume analyzer, Daxor BVA, to the FDA for 510(k) approval. The new device represents a significant advancement in blood volume measurement technology, offering direct quantification of intravascular blood, red blood cell, and plasma volume.
The next-generation analyzer, developed under a U.S. Department of Defense contract, boasts several improvements over its predecessor, the BVA-100™ system, including:
- Three times faster processing
- Significantly simpler operation
- Complete portability
- Point of care analysis capabilities
These enhancements are designed to facilitate seamless integration of advanced blood volume diagnostics into clinical workflows, potentially improving medical care and patient outcomes.
Daxor (DXR) showcased significant presence at the American College of Cardiology's 74th Annual Scientific Session and Expo in Chicago. A key session on Blood Volume Analysis (BVA) versus pressure measurement attracted over 400 clinicians. Duke University Medical Center presented new research confirming BVA as a more precise measure of congestion in heart failure patients.
Dr. Marat Fudim of Duke University Health emphasized that pressure-based assessments often misrepresent true volume status. The Duke study revealed that common proxy markers including urine output, weight change, and biomarkers CA-125 and NT-proBNP did not correlate with intravascular volume. The findings reinforce that volume management, rather than pressure management, should be the primary focus in heart failure treatment.
Daxor (DXR) announces expansion of its blood volume analysis (BVA) technology to three regional healthcare facilities across the U.S. through its Tennessee-based ezBVA Lab service. The expansion includes:
- A Midwest academic medical center for outpatient cardiovascular care
- A Wisconsin primary health center for outpatient syncope assessment
- A Southern New Jersey cardiovascular care program for both inpatient and outpatient settings
The CLIA-certified ezBVA Lab delivers comprehensive BVA results within 24 hours, featuring 98% diagnostic accuracy for tailored fluid management. This expansion demonstrates the growing adoption of Daxor's technology in diverse healthcare settings, aimed at improving patient outcomes while reducing costs.
FAQ
What is the current stock price of DAXOR (DXR)?
What is the market cap of DAXOR (DXR)?
